Drugs / 4-OH tamoxifen
4-OH tamoxifen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03199963 | Aug 2017 → Jan 2019 | breast disorder | BHR Pharma, LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-OH tamoxifen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03199963 ↗ |
| Known as | 4-Hydroxytamoxifen | “4-Hydroxytamoxifen (afimoxifene) gel” NCT03199963 ↗ |
| Known as | afimoxifene | “4-Hydroxytamoxifen (afimoxifene) gel” NCT03199963 ↗ |
| Known as | BHR-700 | “BHR-700 (0.2% 4-OHT gel)” NCT03199963 ↗ |
| Route | Topical | “Subjects will apply the investigational gel to both breasts once per day” NCT03199963 ↗ |